Zydus Lifesciences announced that the US Food and Drug Administration (USFDA) has granted Orphan Drug Designation (ODD) to its investigational therapy Desidustat for the treatment of sickle cell disease. This recognition enhances development incentives, strengthens Zydus’ global R&D pipeline, and underscores its commitment to addressing rare disorders.
Show moreStay Ahead – Explore Now! Envirotech Systems Secures Order Worth 29.4 Million Rupees
Copyright 2024 WOWNEWS 24x7. All rights reserved. The WOWNEWS 24x7 is not responsible for the content of external sites. Read about our approach to external linking.
Powered By Just Imagine
